Life Sciences and Healthcare

Despite solid API market growth, India and China face challenges – including around costs

Companies have chosen India as a sourcing destination for many years due to India’s lower cost structure for manufacturing, labor, materials and equipment. India possesses a large talent pool of chemical engineers and scientists and a large manufacturing capacity focused on regulated markets.  China also has a talented pool of scientists and engineers, a low […]

Causality: Taking disease research beyond pathways

In today’s research landscape, a cell biologist faces into two seemingly endless chasms of content in their regular study of disease understanding and novel therapy development. First, a scientist must address the tremendous amount of knowledge revealed in new molecular biology/genetics publications, and second, the sheer number of data points generated by OMICs technologies for […]

FDA panel recommends device approval but questions sponsor’s clinical trial change

The U.S. Food and Drug Administration (FDA) allows for some flexibility related to changes in clinical trial protocols—for example, with adaptive trials. However, as one sponsor has found out, certain changes can lead to some pointed questions from agency officials. TransMedics Inc., an Andover, Mass.-based device company, is waiting for a decision from the FDA […]

Bolstering domestic industry is key pharma focus in Russia

  The main driving force behind investment into Russia is the Pharma 2020 plan, introduced in 2009. The state-run plan contains goals of producing 90% of vital medicines within Russia to become less dependent on imported medicine. The Russian government has also prioritized the need for the domestic production of fine chemicals. Another key measure […]

The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Poly ADP-ribose polymerase (PARP) inhibitors have created much excitement in the medical community since the demonstration in 2005 of the extreme sensitivity […]